U.S. stock market anomaly | ZaiDing Pharmaceuticals (ZLAB.US) rises more than 10% Zoci granted FDA fast track qualification

According to the Wisdom Financial APP, on Monday, Zai Ding Pharmaceuticals (ZLAB.US) rose more than 10% to $20.50. On the news front, Zai Ding Pharmaceuticals announced on Monday that its self-developed antibody drug conjugate (ADC) targeting DLL3, Zoci (zocilurtatug pelitecan, originally ZL-1310), has been granted fast track designation by the U.S. FDA for the treatment of pulmonary extrapulmonary neuroendocrine carcinoma (epNECs) that has progressed after first-line standard treatment.